View all Press Releases

Acerus Announces Appointment of Ken Yoon as Chief Financial Officer


TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that it has appointed Mr. Ken Yoon to the position of Chief Financial Officer. Mr. Yoon will officially join Acerus on June 1, 2017.

“The Board of Directors and I are delighted to welcome Ken at this important juncture in the development of our company. He brings considerable financial acumen, transactional experience and strategic skills to the table which will be important assets as we move forward with our growth plans,” said Tom Rossi, President and Chief Executive Officer of Acerus.

Mr. Yoon joins Acerus from Vive Crop Protection Inc., where he held the position of CFO and Vice President of Corporate Development as well as Corporate Secretary. While at Vive, he negotiated product license, development and IP agreements with global crop companies and was involved in raising over $35 million in capital to fund operations.

Previous to his time at Vive, Mr. Yoon was with VG Private Equity Partners as their Senior Associate, Investments – Advanced Life Sciences Fund, where he identified new business opportunities for portfolio companies, including various M&A initiatives. Prior to VG Private Equity Partners, he held the position of Strategist, Entrepreneurial Business Centre (EBC) at Ernst & Young. He helped to launch the EBC and then acted as its lead for the Life Sciences sector.

Mr. Yoon is a Chartered Professional Accountant. He also holds a Bachelor of Science degree from the University of Western Ontario, a Bachelor of Laws from Queen’s University and an MBA from the University of Toronto. He has been a council member of the Royal Canadian Institute for the Advancement of Science since 2009 and was awarded the Queen Elizabeth II Diamond Jubilee Medal for contribution to the Advancement of Sciences by the Government of Canada in 2012.

About Acerus

Acerus Pharmaceuticals Corporation is a fully-integrated, Canadian specialty pharmaceutical company engaged in the development, manufacture, marketing and distribution of innovative, branded products in Men’s and Women’s Health. Acerus’ shares trade on TSX under the symbol ASP. For more information, visit and follow us on Twitter and LinkedIn.

Notice regarding forward-looking statements

Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 7, 2017 that is available at Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Source: Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Corporation

Tricia Symmes, 416-509-2116

Chief Operating Officer